enVVeno Medical Corp
Data quality: 83%
NVNO
Nasdaq
Manufacturing
Measuring & Analyzing Instruments
$11.01
▲
$0.06
(0.55%)
Mkt Cap: 7.22 M
Price
$11.01
Mkt Cap
7.22 M
Day Range
$10.79 — $11.05
52-Week Range
$8.67 — $196.70
Volume
3,788
Open $10.80
50D / 200D Avg
$10.62
3.69% above
50D / 200D Avg
$48.16
77.14% below
Quick Summary
Key Takeaways
Negative free cash flow of -15.57 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-62.31%
Below sector avg (-53.47%)
ROIC-51.99%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio13.12
Interest CoverageN/A
Valuation
PE (TTM)
-0.37
Above sector avg (-1.47)
P/B Ratio0.25
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.4 | -1.5 |
| P/B | 0.3 | 1.6 |
| ROE % | -62.3 | -53.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -19.47 M |
| ROE | -62.31% | ROA | -56.50% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -15.57 M |
| ROIC | -51.99% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 13.12 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 29.10 M | Tangible Book Value | 29.45 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.37 | Forward P/E | N/A |
| P/B Ratio | 0.25 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -215.75% | ||
| Market Cap | 7.22 M | Enterprise Value | 5.67 M |
| Per Share | |||
| EPS (Diluted TTM) | -33.06 | Revenue / Share | N/A |
| FCF / Share | -23.75 | OCF / Share | -23.75 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 79.98% |
| SBC-Adj. FCF | -19.36 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -19.47 M | -21.82 M | -23.52 M | -24.67 M | -16.53 M |
| EPS (Diluted) | -33.06 | -1.27 | -1.91 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -20.90 M | -23.83 M | -25.24 M | -24.93 M | -16.89 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 9.98 M | 12.25 M | 13.58 M | 9.91 M | 5.73 M |
| SG&A Expenses | 10.92 M | 11.58 M | 11.66 M | 15.02 M | 11.16 M |
| D&A | 136,000.0 | 189,000.0 | 220,000.0 | 212,000.0 | 149,002.0 |
| Interest Expense | — | — | — | 161,000.0 | 18,709.0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 29.56 M | 44.95 M | 48.64 M | 41.66 M | 57.70 M |
| Total Liabilities | 2.43 M | 2.80 M | 2.44 M | 2.93 M | 3.29 M |
| Shareholders' Equity | 27.13 M | 42.16 M | 46.20 M | 38.73 M | 54.40 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 3.07 M | 1.75 M | 3.62 M | 4.56 M | 54.73 M |
| Current Assets | 28.83 M | 43.73 M | 46.92 M | 39.44 M | 55.04 M |
| Current Liabilities | 2.12 M | 2.10 M | 1.37 M | 1.53 M | 1.58 M |
{"event":"ticker_viewed","properties":{"ticker":"NVNO","listing_kind":"stock","pathname":"/stocks/nvno","exchange":"Nasdaq","country":"US"}}